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ABSTRACT 
Observations about the growth of some microorganisms inhibiting the growth of other microorganisms have been reported since the 
late 1800s. These observations of antibiosis between microorganisms led to the discovery of natural antibacterial. This paper 
deliberates important findings of the educations conducted by numerous national and international combined organizations on a brief 
indication of the antibacterial agents׳ detection in recent years.  In India especially the developing antibiotics, need to institute 
methods for the suitable choice of drug conduct a compound problem involving prescribers, dispensers, and consumers. 
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INTRODUCTION  
a) History 
Before the early 20th century, treatments for infections 
were based primarily on medicinal folklore. Mixtures 
with antimicrobial properties that were used in 
treatments of infections were described over 2000 years 
ago.
1
 Many ancient cultures, including the ancient 
Egyptians and ancient Greeks, used a specially 
selected mold and plant materials and extracts to 
treat infections. 
Synthetic antibiotic chemotherapy as a science and 
development of antibacterial began in Germany 
with Paul Ehrlich in the late 1880s. He then proposed 
the idea that it might be possible to create chemicals that 
would act as a selective drug that would bind to and kill 
bacteria without harming the human host. After 
screening hundreds of dyes against various organisms, 
in 1907, he discovered a medicinally useful drug, the 
first synthetic antibacterial  salvarsan
 




The Hoechst company began to market the compound 
toward the end of 1910 under the name Salvarsan. This 
drug is now known as arsphenamine. The drug was used 
to treat syphilis in the first half of the 20th century. In 
1908, Ehrlich received the Nobel Prize in Physiology or 
Medicine for his contributions to immunology. 
3
 
The first sulfonamide and the first systemically active 
antibacterial drug, Prontosil, was developed by a 
research team led by Gerhard Domagk in 1932 or 1933 
at the Bayer Laboratories of the IG Farben conglomerate 
in Germany, for which Domagk received the 1939 
Nobel Prize in Physiology or Medicine. 
4
 Sulfanilamide, 
the active drug of Prontosil, was not patentable as it had 
already been in use in the dye industry for some years. 
Prontosil had a relatively broad effect against Gram-
positive cocci, but not against enterobacteria. The 
research was stimulated apace by its success. The 
discovery and development of this sulfonamide drug 
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Arsphenamine, also known as salvarsan, discovered in 1907 by Paul Ehrlich. 
 
b) Penicillin and other natural antibiotics  
 
Penicillin, discovered by Alexander Fleming in 1928 
In 1874, physician Sir William Roberts noted that 
cultures of the mold Penicillium glaucum that is used in 
the making of some types of cheese did not display 
bacterial contamination. In 1876, 
6
 physicist John 
Tyndall also contributed to this field. Pasteur conducted 
research showing that Bacillus anthracis would not 
grow in the presence of the related mold Penicillium 
notatum. 
The first known scholarly work to consider the 
therapeutic capabilities of molds resulting from their 
anti-microbial activity. In his thesis, Duchesne proposed 
that bacteria and molds engage in a perpetual battle for 
survival.
7
 Duchesne observed that E. coli were 
eliminated by Penicillium glaucum when they were both 
grown in the same culture. He also observed that when 
he inoculated laboratory animals with lethal doses 
of typhoid bacilli together with Penicillium glaucum, the 
animals did not contract typhoid. 
8
 Unfortunately, 
Duchesne's army service after getting his degree 
prevented him from doing any further 
research. Duchesne died of tuberculosis, a disease now 
treated with antibiotics.
 
In 1928, Sir Alexander Fleming postulated the existence 
of penicillin, a molecule produced by certain molds that 
kill or stops the growth of certain kinds of bacteria. 
Fleming was working on a culture of disease-
causing bacteria when he noticed the spores of a green 
mold, Penicillium chrysogenum, in one of his culture 
plates. 
9
 He observed that the presence of the mold 
killed or prevented the growth of the bacteria. Fleming 
postulated that the mold must secrete an antibacterial 
substance, which he named penicillin in 1928. Fleming 
believed that its antibacterial properties could be 
exploited for chemotherapy. He initially characterized 
some of its biological properties and attempted to use a 
crude preparation to treat some infections, but he was 
unable to pursue its further development without the aid 
of trained chemists.  
Later, Norman Healthy developed the back-extraction 
technique for efficiently purifying penicillin in bulk. 
The chemical structure of penicillin was first proposed 
by Abraham. 
10
 Purified penicillin displayed potent 
antibacterial activity against a wide range of bacteria 
and had low toxicity in humans. Furthermore, its 
activity was not inhibited by biological constituents such 
as pus, unlike the synthetic sulfonamides.  
11
 The 
development of penicillin led to renewed interest in the 
search for antibiotic compounds with similar efficacy 
and safety. For their successful development of 
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penicillin, which Fleming had accidentally discovered 
but could not develop him, as a therapeutic drug, Chain, 
and Florey shared the 1945 Nobel Prize in 
Medicine with Fleming. 
12
 World War II. Gramicidin, 
however, could not be used systemically because of 
toxicity. Tyrocidine also proved too toxic for systemic 
usage. Research results obtained during that period were 
not shared between the Axis and the Allied 
powers during World War II and limited access during 
the Cold War. .  
Antibiotics 
The term antibiotic was first used in 1942 by Selman 
Waksman and his collaborators in journal articles to 
describe any substance produced by a microorganism 
that is antagonistic to the growth of other 
microorganisms in high dilution. 
13
 This definition 
excluded substances that kill bacteria but that are not 
produced by microorganisms ( hydrogen peroxide). It 
also excluded synthetic antibacterial compounds such as 
the sulfonamides. In current usage, the term "antibiotic" 
is applied to any medication that kills bacteria or inhibits 
their growth, regardless of whether that medication is 
produced by a microorganism or not. An 
antimicrobial drug used in the treatment and prevention 
of bacterial infections. 
14
 They may either kill or inhibit 
the growth of bacteria.  Sometimes the term antibiotic 
(which means "opposing life") is used to refer to any 
substance used against microbes, synonymous with an 
antimicrobial. Some sources distinguish between 
antibacterial and antibiotic; antibacterial is used in soaps 
and disinfectants, while antibiotics are used as medicine. 
Antibiotics revolutionized medicine in the 20th century. 
This has led to widespread problems, so much as to 
prompt the World Health Organization to classify 
antimicrobial resistance as a "serious threat is no longer 
a prediction for the future, it is happening right now in 
every region of the world and has the potential to affect 




Antibiotics are used to treat or prevent bacterial 
infections, and sometimes protozoan infections. When 
an infection is suspected of being responsible for an 
illness, but the responsible pathogen has not been 
identified, an empiric therapy is adopted. 
16
 This 
involves the administration of a broad-spectrum 
antibiotic based on the signs and symptoms presented 
and are initiated pending laboratory results that can take 
several days. 
When the responsible pathogenic microorganism is 
already known or has been identified, definitive 
therapy can be started. This will usually involve the use 
of a narrow-spectrum antibiotic. The choice of antibiotic 
given will also be based on its cost. Identification is 
critically important as it can reduce the cost and toxicity 
of the antibiotic therapy and reduce the possibility of the 
emergence of antimicrobial resistance. 
17
 To avoid 
surgery, antibiotics may be given for non-complicated 
acute appendicitis.  
Antibiotics may be given as a preventive measure 
(prophylactic) and this is usually limited to at-risk 
populations such as those with a weakened immune 
system (particularly in HIV cases to prevent 
pneumonia), those taking  immune suppressive 
drugs, cancer patients and those having surgery Their 
use in surgical procedures is to help prevent infection 
of incisions. 
18
 They have an important role in dental 
antibiotic prophylaxis where their use may prevent 
bacteremia and consequent infective endocarditis. 
Antibiotics are also used to prevent infection in cases 
of neutropenia particularly cancer-related.
19
 There are 
many different routes of administration for antibiotic 
treatment. Antibiotics are usually taken by mouth. In 
more severe cases, particularly deep-seated systemic 
infections, antibiotics can be given intravenously or by 
injection.  Topical use is also one of the treatment 
options for some skin conditions including acne and 
cellulitis. 
20
 Advantages of topical application include 
achieving a high and sustained concentration of 
antibiotic at the site of infection; reducing the potential 
for systemic absorption and toxicity, and total volumes 
of antibiotic required are reduced, thereby also reducing 
the risk of antibiotic misuse. 
21
 Topical antibiotics 
applied to certain types of surgical wounds have been 
reported to reduce the risk of surgical site infections. 
However, there are certain general causes for concern 
with topical administration of antibiotics. Some 
systemic absorption of the antibiotic may occur; the 
quantity of antibiotic applied is difficult to accurately 
dose, and there is also the possibility of 





Antibiotics are screened for any negative effects before 
their approval for clinical use and are usually considered 
safe and well tolerated. Some antibiotics have been 
associated with a wide extent of adverse side 
effects ranging from mild to very severe depending on 
the type of antibiotic used, the microbes targeted, and 
the individual patient.  
23
 Side effects may reflect the 
pharmacological or toxicological properties of the 
antibiotic or may involve hypersensitivity or allergic 
reactions. Safety profiles of newer drugs are often not as 
well established as for those that have a long history of 
use. Common side-effects include diarrhea, resulting 
from disruption of the species composition in the 
intestinal flora, resulting, for example, an overgrowth of 
pathogenic bacteria, such as Clostridium difficile. 
24
 
Antibacterial can also affect the vaginal flora and may 
lead to overgrowth of yeast species of the genus.  
Correlation with obesity 
It is unclear whether antibiotics cause obesity in 
humans. Studies have found a correlation between early 
exposure of antibiotics (<6 months) and increased body 
mass (at 10 and 20 months) Another study found that 
the type of antibiotic exposure was also significant with 
the highest risk of being overweight in those 
given macrolides compared to penicillin and 
cephalosporin. 
25
 Therefore, there is a correlation 
between antibiotic exposure in early life and obesity in 
humans, but whether there is a causal relationship 
remains unclear. Although there is a correlation between 
antibiotic use in early life and obesity, the effect of 
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antibiotics on obesity in humans needs to be weighed 
against the beneficial effects of clinically indicated 




Birth control pills 
Well controlled studies on the effect of oral 
contraceptive failure and antibiotics are very limited. 
The majority of studies indicate antibiotics do not 
interfere with birth control pills, such as clinical studies 
that suggest the failure rate of contraceptive pills caused 
by antibiotics is very low (about 1%).Situations that 
may increase the risk of oral contraceptive failure 
include non-compliance (missing taking the pill), 
vomiting or diarrhea. 
27
 Gastrointestinal disorders or 
interpatient variability in oral contraceptive absorption 
affecting ethynyl estradiol serum levels in the 
blood. Women with menstrual irregularities may be at 
higher risk of failure and should be advised to 
use backup contraception during antibiotic treatment 
and for one week after its completion. 
28
 If patient-
specific risk factors for reduced oral contraceptive 
efficacy are suspected, backup contraception is 
recommended.  
Clinicians have recommended that extra contraceptive 
measures be applied during therapies using antibiotics 
that are suspected to interact with oral contraceptives. 
More studies on the possible interactions between 
antibiotics and birth control pills (oral contraceptives) 
are required as well as a careful assessment of patient-
specific risk factors for potential oral contractive pill 




Alcohol   
Interactions between alcohol and certain antibiotics may 
occur and may cause side-effects and decreased 
effectiveness of antibiotic therapy. While moderate 
alcohol consumption is unlikely to interfere with many 
common antibiotics, there are specific types of 
antibiotics, with which alcohol consumption may cause 
serious side-effects. 
30
 Therefore, potential risks of side-
effects and effectiveness depend on the type of antibiotic 
administered. In addition, the efficacy of doxycycline 
and erythromycin succinate may be reduced by alcohol 
consumption.
 
 Other effects of alcohol on antibiotic 
activity include the altered activity of the liver enzymes 
that break down the antibiotic compound.
31
 A 
bactericidal activity of antibacterial may depend on the 
bacterial growth phase, and it often requires ongoing 
metabolic activity and division of bacterial cells. These 
findings are based on laboratory studies, and in clinical 
settings have also been shown to eliminate bacterial 
infection. Since the activity of antibacterial depends 
frequently on its concentration, in vitro characterization 
of antibacterial activity commonly includes the 
determination of the minimum inhibitory concentration 







The emergence of resistance of bacteria to antibiotics is 
a common phenomenon. The emergence of resistance 
often reflects evolutionary processes that take place 
during antibiotic therapy. The antibiotic treatment 
may select for bacterial strains with physiologically or 
genetically enhanced capacity to survive high doses of 
antibiotics.
33
 Under certain conditions, it may result in 
the preferential growth of resistant bacteria, while the 
growth of susceptible bacteria is inhibited by the drug.  
Resistance may take the form of biodegradation of 
pharmaceuticals, such as sulfamethazine-degrading soil 
bacteria introduced to sulfamethazine through medicated 
pig feces. The survival of bacteria often results from an 
inheritable resistance, but the growth of resistance to 
antibacterial also occurs through horizontal gene 
transfer. 
34
 Antibacterial resistance may impose a 
biological cost, thereby reducing the fitness of resistant 
strains, which can limit the spread of antibacterial-
resistant bacteria, for example, in the absence of 
antibacterial compounds. 
35
 Additional mutations, 
however, may compensate for this fitness cost and can 
aid the survival of these bacteria.  Paleontological data 
show that both antibiotics and antibiotic resistance are 
ancient compounds and mechanisms. Useful antibiotic 
targets are those for which mutations negatively impact 
bacterial reproduction or viability.  Acquired resistance 
results from a mutation in the bacterial chromosome or 
the acquisition of extra-chromosomal DNA. 
Antibacterial-producing bacteria have evolved resistance 
mechanisms that have been shown to be like and may 
have been transferred to, antibacterial-resistant strains. 
36
 The spread of antibacterial resistance often occurs 
through vertical transmission of mutations during 
growth and by genetic recombination of DNA by the 
horizontal genetic exchange. For instance, antibacterial 
resistance genes can be exchanged between different 
bacterial strains or species via plasmids that carry these 
resistance genes.   
Antibacterial-resistant strains and species sometimes 
referred to as "superbugs", now contribute to the 
emergence of diseases that were for a while well 
controlled. For example, emergent bacterial strains 
causing tuberculosis that are resistant to previously 
effective antibacterial treatment pose many therapeutic 
challenges. 
37
 Every year, nearly half a million new 
cases of multidrug-resistant tuberculosis  (MDR-TB) are 
estimated to occur worldwide. Many antibiotics are 
frequently prescribed to treat symptoms or diseases that 
do not respond to antibiotics or that are likely to resolve 
without treatment. Also, incorrect or suboptimal 
antibiotics are prescribed for certain bacterial 
infections. The overuse of antibiotics, like penicillin and 
erythromycin, has been associated with emerging 
antibiotic resistance since the 1950s. Widespread usage 
of antibiotics in hospitals has also been associated with 
increases in bacterial strains and species that no longer 
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Research 
The increase in bacterial strains that are resistant to 
conventional antibacterial therapies together with 
decreasing number of new antibiotics currently being 
developed in the drug pipeline has prompted the 
development of bacterial disease treatment strategies 
that are alternatives to conventional antibacterial. 
39
 
Non-compound approaches (that is, products other than 
classical antibacterial agents) that target bacteria or 
approaches that target the host including phage 
therapy and vaccines are also being investigated to 
combat the problem.  
Vaccines 
Vaccines rely on immune modulation or augmentation. 
Vaccination either excites or reinforces the immune 
competence of a host to ward off infection, leading to 
the activation of macrophages, the production 
of antibodies, inflammation, and other classic immune 
reactions. 
40
 Antibacterial vaccines have been 
responsible for a drastic reduction in global bacterial 
diseases. Vaccines made from attenuated whole cells or 
lysates have been replaced largely by less erectogenic, 
cell-free vaccines consisting of purified components, 
including capsular polysaccharides and their conjugates, 






Some antioxidant dietary supplements also contain 
phytochemicals (polyphenols), such as grape seed 
extract, and demonstrate in vitro anti-bacterial 
properties. Phytochemicals can inhibit peptidoglycan 
synthesis, damage microbial membrane structures 
modify bacterial membrane surface hydrophobicity and 
modulate quorum-sensing. 
42
 With increasing antibiotic 
resistance in recent years, the potential of new plant-
derived antibiotics is under investigation.  
CONCLUSION 
Antibiotics have protected millions of exists and 
changed modern medicine, but they are becoming less 
actual. The Essential Elements of Antibiotic healthcare 
workers, health systems, hospitals, clinics, and nursing 
homes can participate as active forces in serving to 
advance antibiotic custom. Antibiotics are used to treat, 
stop, and regulator disease among food creatures and in 
some cases to improve feed utilization. Antimicrobial 
agents enable decontamination or sanitization of animal 
creation premises, transport facility equipment, and 
effective hygiene during food processing, and confirm 
food excellence and protection. Many hospitals have 
already better-quality their antibiotic recommending by 
following the Fundamental Elements. When antibiotic 
programs and follows are accepted, patients obtain the 
best antibiotic treatment. 
 
REFERENCES 
1. Adeyemi, B. F.; Akinyamoju, A. O.; Kolude, B., Association 
of Squamous Cell Carcinoma of the Tongue with Cigarette and 
Alcohol Exposure: A Retrospective Clinicopathological Study. 
West African journal of medicine 2018, 35:117-122. 
2. Zakeri, B.; Lu, T. K., Synthetic Biology of Antimicrobial 
Discovery. ACS synthetic    biology    2013; 2:358-72. 
3. Hamilton-Miller, J. M., Development of the Semi-Synthetic 
Penicillins and Cephalosporins. International journal of 
antimicrobial agents 2008; 31:189-92. 
4. Kalesse, M.; Bohm, A.; Kipper, A.; Wandelt, V., Synthesis of 
Antibiotics. Current topics in microbiology and immunology 
2016; 398:419-445. 
5. Katz, L.; Baltz, R. H., Natural Product Discovery: Past, 
Present, and Future. Journal of industrial microbiology & 
biotechnology 2016; 43:155-76. 
6. Copete-Pertuz, L. S.; Placido, J.; Serna-Galvis, E. A.; Torres-
Palma, R. A.; Mora, A., Elimination of Isoxazolyl-Penicillins 
Antibiotics in Waters by the Ligninolytic Native Colombian 
Strain Leptosphaerulina Sp. Considerations on Biodegradation 
Process and Antimicrobial Activity Removal. The Science of 
the total environment 2018, 630, 1195-1204. 
7. Feigman, M. J. S.; Pires, M. M., Synthetic Immunobiotics: A 
Future Success Story in Small Molecule-Based 
Immunotherapy? ACS infectious diseases 2018; 4:664-672. 
8. Madec, M.; Lallement, C.; Haiech, J., Modeling and 
Simulation of Biological Systems Using Spice Language. PloS 
one 2017; 12:e0182385. 
9. Mohammad, H.; Younis, W.; Ezzat, H. G.; Peters, C. E.; 
AbdelKhalek, A.; Cooper,     B.; Pogliano, K.; Pogliano, J.; 
Mayhoub, A. S.; Seleem, M. N., Bacteriological Profiling of 
Diphenylureas as a Novel Class of Antibiotics against 
Methicillin-Resistant Staphylococcus Aureus. PloS one 2017; 
12:e0182821. 
10. Price, N. P.; Hartman, T. M.; Li, J.; Velpula, K. K.; Naumann, 
T. A.; Guda, M. R.; Yu, B.; Bischoff, K. M., Modified 
Tunicamycins with Reduced Eukaryotic Toxicity That 
Enhance the Antibacterial Activity of Beta-Lactams. The 
Journal of antibiotics 2017; 70:1070-1077. 
11. Serna-Galvis, E. A.; Berrio-Perlaza, K. E.; Torres-Palma, R. 
A., Electrochemical Treatment of Penicillin, Cephalosporin, 
and Fluoroquinolone Antibiotics Via Active Chlorine: 
Evaluation of Antimicrobial Activity, Toxicity, Matrix, and 
Their Correlation with the Degradation Pathways. 
Environmental science and pollution research international 
2017; 24:23771-23782. 
12. Seneviratne, C. J.; Suriyanarayanan, T.; Swarup, S.; Chia, K. 
H. B.; Nagarajan, N.; Zhang, C., Transcriptomics Analysis 
Reveals Putative Genes Involved in Biofilm Formation and 
Biofilm-Associated Drug Resistance of Enterococcus Faecalis. 
Journal of endodontics 2017; 43:949-955. 
13. Wang, W. J.; Wang, Q.; Zhang, Y.; Lu, R.; Zhang, Y. L.; 
Yang, K. W.; Lei, J. E.; He, Y., Characterization of Beta-
Lactamase Activity Using Isothermal Titration Calorimetry. 
Biochimica et biophysica acta 2017; 1861:2031-2038. 
14. Serna-Galvis, E. A.; Ferraro, F.; Silva-Agredo, J.; Torres-
Palma, R. A., Degradation of Highly Consumed 
Fluoroquinolones, Penicillins and Cephalosporins in Distilled 
Water and Simulated Hospital Wastewater by Uv254 and 
Uv254/Persulfate Processes. Water research 2017; 122:128-
138. 
15. Morris, D. O.; Loeffler, A.; Davis, M. F.; Guardabassi, L.; 
Weese, J. S., Recommendations for Approaches to Meticillin-
Resistant Staphylococcal Infections of Small Animals: 
Diagnosis, Therapeutic Considerations and Preventative 
Measures.: Clinical Consensus Guidelines of the World 
Association for Veterinary Dermatology. Veterinary 
dermatology 2017; 28:304-e69. 
16. Bhowmick, T.; Kirn, T. J.; Hetherington, F.; Takavarasha, S.; 
Sandhu, S. S.; Gandhi, S.; Narayanan, N.; Weinstein, M. P., 
Collaboration between an Antimicrobial Stewardship Team 
and the Microbiology Laboratory Can Shorten Time to 
Directed Antibiotic Therapy for Methicillin-Susceptible 
Staphylococcal Bacteremia and to Discontinuation of 
 Singh et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2018; 8(5-s):35-40         
ISSN: 2250-1177                                                                               [40]                                                                             CODEN (USA): JDDTAO 
Antibiotics for Coagulase-Negative Staphylococcal 
Contaminants. Diagnostic microbiology and infectious disease 
2018. 
17. Bojanic, L.; Markovic-Pekovic, V.; Skrbic, R.; Stojakovic, N.; 
Ethermanovic, M.; Bojanic, J.; Furst, J.; Kurdi, A. B.; 
Godman, B., Recent Initiatives in the Republic of Srpska to 
Enhance Appropriate Use of Antibiotics in Ambulatory Care; 
Their Influence and Implications. Frontiers in pharmacology 
2018; 9:442. 
18. Page-Shipp, L.; Lewis, J. J.; Velen, K.; Senoge, S.; Zishiri, E.; 
Popane, F.; Chihota, V. N.; Clark, D.; Churchyard, G. J.; 
Charalambous, S., Household Point of Care Cd4 Testing and 
Isoniazid Preventive Therapy Initiation in a Household Tb 
Contact Tracing Programme in Two Districts of South Africa. 
PloS one 2018; 13:e0192089. 
19. Schellack, N., et al., A Situational Analysis of Current 
Antimicrobial Governance, Regulation, and Utilization in 
South Africa. International journal of infectious diseases : IJID 
: official publication of the International Society for Infectious 
Diseases 2017; 64:100-106. 
20. Boyles, T. H.; Naicker, V.; Rawoot, N.; Raubenheimer, P. J.; 
Eick, B.; Mendelson, M., Sustained Reduction in Antibiotic 
Consumption in a South African Public Sector Hospital; Four 
Year Outcomes from the Groote Schuur Hospital Antibiotic 
Stewardship Program. South African medical journal = Suid-
Afrikaanse tydskrif vir geneeskunde 2017; 107:115-118. 
21. Dunn, J.; Zhang, Q.; Weeks, M. R.; Li, J.; Liao, S.; Li, F., 
Indigenous Hiv Prevention Beliefs and Practices among Low-
Earning Chinese Sex Workers as Context for Introducing 
Female Condoms and Other Novel Prevention Options. 
Qualitative health research 2017; 27:1302-1315. 
22. Teklay, G.; Teklu, T.; Legesse, B.; Tedla, K.; Klinkenberg, E., 
Barriers in the Implementation of Isoniazid Preventive 
Therapy for People Living with Hiv in Northern Ethiopia: A 
Mixed Quantitative and Qualitative Study. BMC public health 
2016; 16:840. 
23. Zalmanovici Trestioreanu, A.; Barua, A.; Pertzov, B., 
Cyclamen Europaeum Extract for Acute Sinusitis. The 
Cochrane database of systematic reviews 2018; 5:CD011341. 
24. Menon, A.; Soman, R.; Rodrigues, C.; Phadke, S.; Agashe, V. 
M., Careful Interpretation of the Wound Status Is Needed with 
Use of Antibiotic Impregnated Biodegradable Synthetic Pure 
Calcium Sulfate Beads: Series of 39 Cases. Journal of bone 
and joint infection 2018; 3:87-93. 
25. De Luna-Preitschopf, A.; Zwickl, H.; Nehrer, S.; 
Hengstschlager, M.; Mikula, M., Rapamycin Maintains the 
Chondrocytic Phenotype and Interferes with Inflammatory 
Cytokine Induced Processes. International journal of molecular 
sciences 2017; 18. 
26. Dumitrache, F.; Gheorghita, E., [Family Planning with 
Different Contraceptive Methods]. Revista medico-
chirurgicala a Societatii de Medici si Naturalisti din Iasi 1991; 
95:187-96. 
27. Thiba, A.; Umar, C. A.; Myende, S.; Nweke, E.; Rumbold, K.; 
Candy, G., Differences in Microbiome in Rat Models of 
Cardiovascular Disease. South African journal of surgery. 
Suid-Afrikaanse tydskrif vir chirurgie 2017; 55:71. 
28. Sidener, H. M.; Park, B.; Gao, L., Effect of Antibiotic 
Administration During Infancy on Growth Curves through 
Young Adulthood in Rhesus Macaques (Macaca Mulatta). 
Comparative medicine 2017; 67:270-276. 
29. Han, D. Y.; Fraser, A. G.; Dryland, P.; Ferguson, L. R., 
Environmental Factors in the Development of Chronic 
Inflammation: A Case-Control Study on Risk Factors for 
Crohn's Disease within New Zealand. Mutation research 2010; 
690:116-22. 
30. Miller, D. M.; Helms, S. E.; Brodell, R. T., A Practical 
Approach to Antibiotic Treatment in Women Taking Oral 
Contraceptives. Journal of the American Academy of 
Dermatology 1994; 30:1008-11. 
31. Zhanel, G. G.; Siemens, S.; Slayter, K.; Mandell, L., Antibiotic 
and Oral Contraceptive Drug Interactions: Is There a Need for 
Concern? The Canadian journal of infectious diseases = 
Journal canadien des maladies infectieuses 1999; 10:429-33. 
32. Leclercq, S.; Starkel, P.; Delzenne, N. M.; de Timary, P., The 
Gut Microbiota: A New Target in the Management of Alcohol 
Dependence? Alcohol 2018. 
33. Reza, A. S.; Anand, D.; Cheng, S. H.; Anand, D., Rare Cause 
for a Common Presentation: Isolated Pulmonary Valve 
Endocarditis yet Another Mimicker. BMJ case reports 2018; 
2018. 
34. Teles, G. H.; da Silva, J. M.; Andrade Mendonca, A.; de 
Morais, M. A. J.; de Barros Pita, W., First Aspects on Acetate 
Metabolism in the Yeast Dekkera Bruxellensis: A Few Keys 
for Improving Ethanol Fermentation. Yeast 2018. 
35. Bellio, P.; Luzi, C.; Mancini, A.; Cracchiolo, S.; 
Passacantando, M.; Di Pietro, L.; Perilli, M.; Amicosante, G.; 
Santucci, S.; Celenza, G., Cerium Oxide Nanoparticles as 
Potential Antibiotic Adjuvant. Effects of Ceo2 Nanoparticles 
on Bacterial Outer Membrane Permeability. Biochimica et 
biophysica acta 2018. 
36. Kadlec, K.; Schwarz, S., Antimicrobial Resistance in 
Bordetella Bronchiseptica. Microbiology spectrum 2018, 6. 
37. Koen, N.; van Breda, S. V.; Loots, D. T., Elucidating the 
Antimicrobial Mechanisms of Colistin Sulfate on 
Mycobacterium Tuberculosis Using Metabolomics. 
Tuberculosis 2018; 111:14-19. 
38. Levitus, M.; Perera, T. B., Vancomycin-Resistant Enterococci 
(Vre). In Statpearls, Treasure Island (FL), 2018. 
39. Lou, W.; Venkataraman, S.; Zhong, G.; Ding, B.; Tan, J. P. K.; 
Xu, L.; Fan, W.; Yang, Y. Y., Antimicrobial Polymers as 
Therapeutics for Treatment of Multidrug-Resistant Klebsiella 
Pneumoniae Lung Infection. Acta biomaterialia 2018. 
40. Luan, Y.; Sun, Y.; Duan, S.; Zhao, P.; Bao, Z., Pathogenic 
Bacterial Profile and Drug Resistance Analysis of Community-
Acquired Pneumonia in Older Outpatients with Fever. The 
Journal of international medical research 2018, 
300060518786915. 
41. Jia, X.; Li, C.; Cao, J.; Wu, X.; Zhang, L., Clinical 
Characteristics and Predictors of Mortality in Patients with 
Candidemia: A Six-Year Retrospective Study. European 
journal of clinical microbiology & infectious diseases : official 
publication of the European Society of Clinical Microbiology 
2018. 
42. Mostaghim, M.; Snelling, T.; Katf, H.; Bajorek, B., Paediatric 
Antimicrobial Stewardship and Safe Prescribing: An 
Assessment of Medical Staff Knowledge and Behaviour. 
Pharmacy practice 2018; 16:1198. 
 
 
 
 
 
